These findings supported our hypothesis that PARD3 overexpression at the tumour initiation stage of hepatic diseases, which is probably due to a genetic instability-induced amplification mutation, contributes to tumorigenesis and progression in HCC. This evidence concerns the gene PARD3 and hepatocellular carcinoma.